Cell therapies for tendons: old cell choice for modern innovation. by Petrou, I.G. et al.
Review article: Medical intelligence | Published 7 August 2014, doi:10.4414/smw.2014.13989
Cite this as: Swiss Med Wkly. 2014;144:w13989
Cell therapies for tendons: Old cell choice for modern
innovation
Ilias G. Petrou*, Anthony Grognuz*, Nathalie Hirt-Burri, Wassim Raffoul, Lee Ann Applegate
Plastic, Reconstructive and Hand Surgery, Unit of Regenerative Medicine, University Hospital of Lausanne, Switzerland
* Considered as equal principal co-authors
Summary
Although tissue engineering and cell therapies are becom-
ing realistic approaches for medical therapeutics, it is likely
that musculoskeletal applications will be among the first to
benefit on a large scale. Cell sources for tissue engineer-
ing and cell therapies for tendon pathologies are reviewed
with an emphasis on small defect tendon injuries as seen
in the hand which could adapt well to injectable cell ad-
ministration. Specifically, cell sources including tenocytes,
tendon sheath fibroblasts, bone marrow or adipose-derived
stem cells, amniotic cells, placenta cells and platelet-de-
rivatives have been proposed to enhance tendon regen-
eration. The associated advantages and disadvantages for
these different strategies will be discussed and evolving
regulatory requirements for cellular therapies will also be
addressed. Human progenitor tenocytes, along with their
clinical cell banking potential, will be presented as an al-
ternative cell source solution. Similar cell banking tech-
niques have already been described with other progenitor
cell types in the 1950’s for vaccine production, and these
“old” cell types incite potentially interesting therapeutic
options that could be improved with modern innovation for
tendon regeneration and repair.
Key words: cell therapy; progenitor; tenocytes; hand
surgery; flexor tendon; neotendon; tendon regeneration;
tendon tissue engineering
Introduction
Tendon disorders are frequent and create functional and
productivity problems in sports and in the workplace. In-
complete healing of tendon injuries not only leads to dis-
ability, but can also be associated with debilitating pain.
Accidents with acute tendon laceration of the hand are par-
ticularly common. Approximately 1,775 new cases are re-
ported in Switzerland each year with a mean insurance
cost of 23,843 CHF [1]. The Swiss hand surgeon, Claude
Verdan, was the first to introduce the classification of flex-
or tendon injuries, separating them into five anatomical
zones [2]. There are also associated pathologies of tendons
and ligaments that can frequently occur with hand overuse,
degenerative diseases and aging. These can promote joint
instability and arthritis and eventually may require surgical
Figure 1
Tendon structure, histology and cell culture.
Ultrastructure of tendon showing longitudinal fibres and histological
sections stained with haematoxylin and eosin depicting extracellular
matrix colored in pink (~80% composition) and cellular components
mainly with tenocytes stained in blue (~20% composition)(horse
tendon for illustration). Primary cultures from tissue can be
developed by culturing cells in minimal medium (DMEM + 10% FBS
+ 1% glutamine) for approximately 1 week in a monolayer culture to
provide “fibroblast-like” pure tenocyte populations (human
progenitor tenocytes).
Figure 2
Tendon pathologies and therapeutic strategy.
Tendon pathologies can be either acute or degenerative.
Degenerative therapies could be treated with biological cellular
therapies with injectable forms to delay degenerative responses
and more invasive surgery. Acute injuries, depending on their
severity, could be treated with either non-invasive to invasive
technique with cells in viscous biogels to complex neo-tissue
constructs.
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intervention. Following the pioneering endeavors of tendon
surgery, modern therapeutic strategies with primary suture
and precocious-controlled motion have been developed
with good but not always ideal results.
On the pathophysiological level, intrinsic tenocyte regen-
erative response, adequate nutrition and prevention of ad-
hesions are some of the key elements that have to be con-
sidered in order to achieve an optimal functional result after
tendon injury. Despite early surgical treatment and mobil-
isation, adhesions are frequent and secondary tendon rup-
ture is still a major concern. Joint instability is usually
the consequence of trauma to bone and degeneration of
Figure 3
Progenitor human tenocyte cell bank production, capacity and
usage for off-the-shelf therapeutic options for tendinopathies.
From one single tendon tissue (2 mm3, organ donation of foetal
Achilles tendon tissue at 14 weeks gestation), clinical cell banks
can be produced including parental primary cultures, Master and
Working Cell Banks that contain 200 vials each of progenitor
tenocytes at low passages (P. 3–6). Expansion of cells produces
high quantities of cells that can be stocked in vapor phase of liquid
nitrogen (–165 °C) providing cell stocks for hundreds of thousands
of patients. Cells can be administered in hydrogels or on other
delivery systems for testing in animal models and pre-clinical
patient treatments in the process for therapeutic agent
development.
Figure 4
Good Clinical Practice and Good Manufacturing Practice
associated with cellular therapeutics.
Current Good Clinical Practices (cGCP) are necessary to begin the
process of cellular therapies and tissue engineering with detailed
protocols for organ donation and biopsy processing. Tissue and
cellular handling then needs to abide by Current Good
Manufacturing Processes (cGMP) which include specific protocols
for infrastructure, equipment and personnel. cGCP is then needed
for appropriate administration of cellular therapies. Thus, the entire
process requires high collaboration between biologists, technicians,
nurses and surgeons.
cartilage. Tendon transfers are used to stabilise the joint,
but treatment failures are frequent where there is tendon
degeneration. It has been proposed that cell stimulation
could prevent surgical failure. Tendon regeneration is a
time consuming procedure because of slow metabolism in
adult tenocytes. Immediately following an injury an in-
flammatory phase takes place, during which chemo-attract-
ive substances are released to recruit and stimulate teno-
cytes. After a few days and during the first few weeks, the
second step of healing is controlled by tenocytes and mac-
rophages and there is a high deposition of matrix, mostly
composed of type 3 collagen. After one or two months,
a third phase appears with the extracellular matrix (ECM)
continuing to be produced but with a higher amount of type
1 collagen. The tissue is reorganised and becomes more
and more aligned. This process takes as long as one year
or more, with the cell density and activity diminishing with
time [3, 4].
The architecture and orientation of the collagen fibres of
the tendon are of paramount importance, providing an ex-
quisite anatomical structure assuring elasticity, mobility
and tensile strength and therefore becoming a functional
tissue with unique biomechanical qualities (fig. 1A & B).
The role of the tendon is to provide correct transmission
of forces between muscle and bone and to protect tension
and compression of structures upon forces. This conjunct-
ive tissue can come in various forms and lengths [3, 5, 6].
Interestingly, the composition of tendon is mostly ECM at
80% and cells at approximately 20% [7] with 90–95% of
the cells being tenocytes [3, 5]. A minor portion of chon-
drocytes, synovial, vascular and tendon stem cells can also
be detected. The longitudinal cells present in histological
sections (fig. 1B) represent tenocytes and are distributed
fairly uniformly throughout the ECM and when cultured
from primary tissue form “fibroblastic-like” cells in 2–D
Figure 5
Regulatory requirements for cellular therapy products.
Regulatory requirements have become more extensive for cellular
therapies and tend towards conservative drug development in their
production, pre-clinical testing and clinical trials. Blood products
also have to be produced under cGMP and only in institutions with
a license for manipulation. Organs, cells and tissues (PRP, adipose,
bone marrow, skin, cartilage, tendon etc.) need to be processed
with environmental monitoring and full quality assurance with cGMP
processing through to the final formulation and delivery to the
patient.
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culture (fig. 1C). The ECM is mainly composed of collagen
fibres representing 65–80% of tendon dry matter with Type
I and III being the most frequent (95% Type I) [6]. Elast-
ic fibres (1–2%), proteoglycans along with glycoproteins
(less tan 1%) and inorganic molecules (less than 0.2%) are
the remaining elements of the ECM [5].
In the case of injury, the healed tendon cannot restore its
exact natural structure, resulting in the formation of scar
tissue which weakens its overall functional abilities [8]. In
clinical practice it is frequently observed that patient re-
covery is long and full strength mobilisation takes almost
3 months after the time of the injury to return. Tendon in-
juries can be classified as acute or degenerative conditions
(fig. 2). Acute injuries associated with partial ruptures or
fissures could be treated first with injectable functional cell
populations before turning towards more invasive tissue
replacement. Tendinopathies with degenerative conditions
could be stabilised with injectable biological cell therapy
solutions in order to delay any surgical procedures. With
tissue defects, the length of time before primary repair, the
failure of the primary closure and enhanced chances of re-
rupture are common problems encountered. Under these
circumstances, the use of tendon grafts or transfers is some-
times necessary (fig. 2). However, these procedures are as-
sociated with donor site morbidity (if autologous graft), in-
creased operating time, risk of infection and higher cost.
These drawbacks have promoted translational research in
the search for solutions of off-the-shelf tendon engineered
constructs and cellular therapies that could be available
whenever and wherever needed. The optimal result of new
therapeutic strategies would be the achievement of a scar-
free regenerated tissue. Cadaveric de-cellularised tendons
are routinely used and new tissue engineering strategies
would be important for clinical use. As for any tissue en-
gineering therapeutic strategy, the cell source and type is
crucial. The implicated cells should be easy to collect, eas-
ily and rapidly cultured and expanded, and should pos-
sess maximum stability of the desired phenotype which
would assure patient safety upon implantation. In addition,
they should also possess a high tendon formation potential
without triggering an immunological reaction of the recipi-
ent patient.
In this short review on innovation we will present the ex-
isting cell sources used in cellular therapies of tendon with
their advantages and drawbacks, and we will present the
potential use of human allogenic progenitor tenocytes for
the repair and enhancement of tissue regeneration of the
tendon.
Embryonic cell sources for tendon tissue engineering
applications
Embryonic stem cells (ESCs) have been proposed as a cell
source for tendon repair and regeneration. These are undif-
ferentiated cells which are able to create all cell types and
the original tissue source is the early age embryo (around
five days following ovum fertilisation). The derived cells
are “totipotent” until eight cell divisions occur. Then, ap-
proximately 2 weeks post-fertilisation, the cells become
pluripotent and can no longer develop into another embryo,
but they can develop into every cell type with proper stim-
ulation (i.e. growth factors). All of these stages of develop-
ment up to 8 weeks post-fertilisation are considered to be
an embryo.
A tendon model derived from ESCs was developed suc-
cessfully and grafted in a rat. Maturation and differenti-
ation of the cells into a tenocyte-type was achieved and ob-
served 30 days after implantation. Using the same cells in
a fibrin gel to treat rat patellar tendons led to better struc-
tural and functional results than the controls with fibrin gel
only. The cells survived for 4 weeks and activated the in-
trinsic tendon regeneration procedure with no presence of
ectopic tissue or teratomas. However, ESCs have the poten-
tial to differentiate into many phenotypes and the presence
of factors like GDF5 and BMP2 in the wound could poten-
tially lead to the formation of bone or cartilage tissues [9].
In a large animal model with induced horse flexor tendonit-
is (collagenase gel – physical defect), the injection of ESCs
to the injured tendon led to an important clinical ameliora-
tion. The double-blinded experiment using MRI as well as
ultrasound analysis showed improved structural changes in
the animals treated with ESCs over placebo [10] but could
not define the specific mechanism of amelioration through
exogenous cell transplant, local cytokine or immunological
modulation or simply by the stimulation of environmental
endogenous horse cells.
The use of ESCs remains fairly complicated on the technic-
al front with high concerns in terms of consistency and se-
curity of the cells as they could dedifferentiate when intro-
duced into an in vivo environment. Cultures of these stem
cell types are technically very demanding since the amount
of tissue to begin the culture is very small (<100 cells)
and up-scaling the stem cells in an undifferentiated state
requires many growth factor supplements. In addition, in
many countries ethical issues for the use of embryonic stem
cells have been associated with specific directives and li-
censes to allow cell manipulation and research. More soph-
isticated techniques of cell encapsulation and cellular clon-
ing could provide strategies to improve the delivery of the
correct cell population and therefore provide an allogenic
(cells not from the same patient) cell source ready-for-use,
which would address safety issues for the patient.
Adult cell sources for tendon tissue engineering
applications
Various adult cell sources are under current research and
development to achieve tendon regeneration. The tissue en-
gineering strategies can thereby be described depending on
the differentiation level of the cells used and on the ori-
ginal tissue source. In addition to the above described em-
bryonic and allogenic cell source, autologous cells have
also been proposed and various adult stem cell populations
have been envisioned for tendon repair. Cell sources imple-
mented include: i) isolated, cultured “mesenchymal cells”
(MSCs) from bone marrow (BM-MSCs), adipose tissue
(AD-MSCs); ii) fully differentiated cell lineages such as
tenocytes, and; iii) blood-derivatives such as platelets or
plasma-enriched platelet preparations (PRP).
Fresh blood or bone marrow have been extensively used
for over 40 years, since the beginning of the tissue en-
gineering era. Although cells from fresh bone marrow or
blood are accessible without much effort, allotransplanta-
tion remains difficult as these transplantations could lead
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to an acute graft-versus host disease [11, 12]. This is why
modern cell-based therapeutic techniques focus on the use
of specific “purified” and culture expanded lineages. In-
terestingly, Osiris Therapeutics demonstrated in 1997 that
BM-MSCs isolated by density gradient, purified to elim-
inate non-MSC cell sources and expanded in cell culture,
could be used as a secure allogenic cell source for different
clinical affections [13]. The first clinical trials using BM-
MSCs allogenic stocked cells for burns and wounds will
take place at the University of Miami as they were awarded
a Department of Defense and Armed Forces Institute of
Regenerative Medicine Grant (DOD-AFIRM) for tissue re-
pair (http://med.miami.edu/news/miller-school-physician-
scientists-receive-3–million-defense-grant-to-treat/). Com-
bining stem cells with autografting techniques used in burn
wounds may help in diffusion of the necessary nutrients,
growth factors and oxygen for successful transplantation.
Likewise, adipose cells derived from the stromal fraction
have been shown to improve diffusion and help overall tis-
sue homeostasis in a mouse model to date [14]. Addition-
ally, other stem cell sources such as tonsil mesenchymal
cells can aid in the preparation of skin engineered grafts
[15] and full lymphatic vascular systems can be linked to
skin grafts with the development of lymphatic capillaries
constructed in vitro [16]. Especially for burn patients these
techniques need to be continually improved and optimised
to allow shorter production and earlier delivery times to the
patient [17].
Both adipose-derived and bone-marrow-derived MSCs
have been used for tendon repair and regeneration potential
in animal models including rats, horses, and sheep [18–21].
Only slight improvements have been reported in these
models and the regeneration quality cannot be compared to
that seen intrinsically in foetal tendon [10, 22, 23]. These
cell types have also been used on acellularised allogenic
tendons or on various scaffolds and tested in animal mod-
els. The optimal goal is to produce a bioengineered con-
struct with high force before failure, adequate tensile stiff-
ness and absence of calcifications [24–27]. So far in human
trials, autotransplantation of mononuclear stem cells ex-
tracted from the iliac crest has given encouraging results in
terms of safety and ability to enhance intrinsic tendon re-
generation [28].
Each cell type possesses different advantages and disad-
vantages. MSCs isolated from different tissue could present
immunological advantages for autologous use. As only one
out of every 100,000 cells derived from bone marrow is a
stem cell, a technically demanding procedure of isolation
and expansion is needed. AD-MSCs are more readily avail-
able (>100–fold compared to BM-MSC) and have better
growth capacity in vitro. Although the use of MSCs has
shown tendon regenerative properties, the formation of cal-
cifications in almost all the experimental models prevents
their establishment as a successful bioengineered thera-
peutic agent for tendons. Recently discovered tendon stem
cells [29] could potentially allow regeneration with less
calcification. Unfortunately it is difficult to harvest these
cells in an autologous tendon.
It is possible that differentiated cells will be more compet-
ent in the in vivo environment due to their higher produc-
tion of specific components of the extracellular matrix and
lower de-differentiation potential. Cell choices from local
tendon environment such as tenocytes, and tendon sheath
fibroblasts were proposed [27] and comparisons between
adipose-derived MSC and bone-marrow derived MSC to
these two differentiated cell types were assessed for their
qualities both in vitro and in vivo. As all cell types were
viable and seemed to deposit matrix, differentiated cell
sources might avoid calcification formation and prove
more useful. However, adult tendon cells present the same
issue as tendon stem cells and an autologous source does
not yet seem technically imaginable.
Another recent popular cell source for tendon regeneration
is platelets. Platelet rich plasma (PRP) can be used alone
or with biocompatible scaffolds, providing better structural
results resulting in increased functional outcomes [30, 31].
Until now, PRP is used as an autotransplantation as there
is always a small but existing risk of immunological re-
actions in the case of allotransplantation [32]. On the one
hand there is still strong controversy regarding the real pos-
itive effect that this therapeutic agent can obtain [33] but on
the contrary the isolation and preparation can be done rap-
idly and inexpensively [34].
Progenitor cell sources in tissue engineering
applications
Placenta, umbilical cord or even amniotic liquid contain
various types of foetal progenitor cells that have been em-
ployed in bioengineering [35–37]. Besides these above
mentioned tissues, most foetal cell research is based on
specific material derived at the latter end of the first tri-
mester (11 to 14 weeks of gestation). At this stage, cell lin-
eages with tissue specific cells can be established. The tis-
sue can be considered an organ donation when the mother-
donor is contacted only after her decision to proceed with a
voluntary pregnancy interruption, when she (and her part-
ner) gives an informed consent and when there is no pay-
ment [38]. This procedure is authorised by legislation in
most countries.
The use of foetal tissues or cells in research began in the
laboratories of immunologists and neurologists. The polio
vaccine, which led to a Nobel Prize for Medicine in 1954
to American immunologists, was developed using cultures
of human foetal cells which are still used in contemporary
vaccine development today. Transplantation of foetal neur-
al cells has been used to treat conditions such as Hunting-
ton’s [39, 40] or Parkinson’s disease [41]. Similarly, foetal
transplants have been used for spinal cord affections or in-
juries by providing encouraging results in motor function
recovery and also by offering a safe transplantation proced-
ure for patients [42–45]. Moreover, human foetal liver cells
have been used for more than 25 years to treat severe im-
munodeficiency, haematological disorders and congenital
disorders of metabolism [46].
Recently, liver failures and diabetes have been targeted by
foetal cell therapy strategies [47]. Better understanding of
developmental embryology has substantially helped tech-
nological progress. Studies have also revealed important
inductive signals and transcription factors that can play
crucial roles in the differentiation of hepatocytes and b-
cells from various stem and progenitor cell types [48]. It
should be noted that human foetal liver cells were suc-
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cessfully isolated to treat end-stage liver disease. In a case
report it was shown that the patient model for end-stage
liver disease (MELD) score improved significantly within
the first 18 months of follow-up [49]. In another study in-
cluding 25 patients, clinical and biochemical parameters
improved, patients did not present with hepatic enceph-
alopathy and their mean MELD score decreased during 6
months of observation [50].
In recent years, three-dimensional biological bandages, de-
veloped from human foetal skin progenitor cells have been
used to treat burns in children and also for chronic wounds
[51, 52]. With this particular technique, cells from one ded-
icated cell bank can be expanded to produce over 35 x
109 tissue engineering skin constructs (9 x12 cm) provid-
ing an off-the shelf cell-based therapy [53]. Following this
approach, human foetal bone cells [54] and chondro-pro-
genitor cells [55] have been used as potential regenerative
agents for human skeletal tissue, and depending on delivery
systems, the cells can be used either in injectable tech-
niques for difficult to treat areas or on scaffolds for cavity
filling [56]. Surprisingly, tendon tissue engineering using
foetal progenitor cells has barely begun to be investigated.
Lately, our group has studied the characteristics of human
progenitor tenocytes for a better comprehension of their
biology in vitro (http://www.unil.ch/webdav/site/fbm/
shared/recherche/FBM_Day_2012/
FBMDAY_ABSTRACTBOOK_2012_FINAL.pdf, ab-
stract on p.93) and to evaluate their potential use for tendon
tissue engineering and for the production of a biocompat-
ible neo-tendon. A short description follows below.
Potential of human progenitor tenocytes for tendon
tissue engineering applications
Up to now, it has been shown that the determining factor
in cell therapies is the cell choice and technical specific-
ations that are related to their collection, culture, expan-
sion, storage and stability. In addition, therapeutically, the
cells should have high tissue regenerative properties, pro-
duce low or no immunological induced reactions, and have
no pro-inflammatory issues. In Figure 3, a clinical cell bank
of human progenitor tenocytes is depicted that can be de-
veloped in a very short time period from one single or-
gan donation of achilles heel tendon (~2 mm3). These cells
have been developed in a registered transplantation pro-
gramme in Switzerland since 2007 (08.2007, protocol #62/
07: Development of foetal cell banks for tissue engineer-
ing) [34]. The primary culture or parental cell bank can be
produced in less than 14 days using a simple medium as nu-
trient (Dulbecco’s Modified Eagles Medium [DMEM] sup-
plemented with 10% foetal bovine serum and 1% glutam-
ine) (fig. 3A). Master and working cell bank vials (MCB
& WCB) of 1–1010 cells can be stored at –165 °C in the
vapor phase of liquid nitrogen for at least 5 years with no
incidence on stability (fig. 3B). Other progenitor cell types
have been shown to remain stable for 20 years to date (i.e.
skin). From the original 2 mm3 of tissue, it would be pos-
sible to develop around 200 vials of a MCB and an equi-
valent quantity of WCB vials. The overall potential of one,
unique organ donation can thus be illustrated in that at least
35 x 109 treatments could be produced from the clinical cell
bank. The cells produced could be delivered either in hy-
drogels to allow minimal invasive options or within a scaf-
fold to provide possibilities for larger defect repair and re-
generation (fig. 3C).
Evolving regulatory requirements for cellular
therapies
The main reason why cellular therapies have not been im-
plemented more rapidly in the clinical setting is because
of the fluctuating regulatory requirements that have sur-
rounded cellular products over the last years. The EU reg-
ulation on advanced therapy medicinal products (ATMP)
was adopted in all European member states in 2008 and
Switzerland modified its Transplantation Act in July of
2007 (Federal Act on the Transplantation of Organs, Tis-
sues and Cells of 8 October 2004, RS 810.21). Since these
dates, all cellular products must be in compliance with Cur-
rent Good Clinical Practice (cGCP) guidelines for their
procurement and collection, and with Current Good Manu-
facturing Procedures (cGMP) for the production and man-
ufacturing of cells and tissues. These new regulations im-
pose strict criteria for the production of cellular products
and the environment for which they are produced (fig. 4 &
5). The necessary requirements can be assimilated to the in-
dustry that produces vaccines for world-wide use. As a res-
ult, cellular products and therapies used in early clinical tri-
als require hospital settings that have appropriate licensed
clean-rooms for stocking and manufacturing of cells; a ma-
jor task that takes time and extremely high budgets. Most
of the major hospitals in Switzerland have invested in fa-
cilities or are investing in them to assure cellular therapeut-
ic options. These types of clean rooms and quality assur-
ance (QA) systems associated with them are now necessary
even for PRP preparations following a recent decision by
SwissMedic (August, 2013: http://www.swissmedic.ch/zu-
lassungen/00196/01956/index.html?lang=fr). All prepara-
tions of blood and serum derivatives for the treatments of
tendinopathies are obliged to be considered as medicinal
products under the interpretation of the Therapeutic
Products Act (Federal Act on Medicinal Products and Med-
ical Devices of 15 December 2000, TPA, RS 812.21). Con-
sequently, preparations can only be prepared in appropriate
laboratories that have a license for manufacturing and fab-
rication must respect “GMP on a small industrial scale”,
which are edited by SwissMedic in Pharmacopoea Helvet-
ica (11.1, chapter 20.1 and 21.1). Clinical indications that
are regularly treated with these PRP and associated pre-
parations include achilles tendinopathy, patellar tendino-
pathy (‘jumper’s knee’), rotator cuff disorders, calcaneal
and plantar fasciitis in the foot, muscle strains, ligament
sprains, articular cartilage injury and even for preparation
before hair transplants. In the field of hand surgery, the
conditions including lateral epicondylitis (‘tennis elbow’),
medial epicondylitis (golfer's elbow), osteoarthritis, acute
flexor/extensor tendon rupture/laceration or even hand re-
juvenation techniques will now need to follow these new
strict regulations. Consequently, any product destined to be
transferred to patients, which is composed of organs, cells
and living tissues from autologous, allogenic or xenogen-
eic sources (PRP, MSCs, skin progenitor cells, tenocytes)
will need to follow environmental monitoring and differ-
ent degrees of GMP manufacturing. Manufacturing will
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include all manipulations ranging from simple tissue and
cell separation techniques (i.e. centrifugations) to the more
complex manipulations of cell culturing and extensive cell
separation (fig. 5). With the advancement of technology
and the ever increasing interest in tendon regeneration re-
search, tendon pathologies could be included in more com-
plex cell-based therapeutic strategies in the near future.
Benefits for patient care with these new innovative ther-
apies offer promise in repairing, replacing or restoring the
functionality of damaged tissues and in the management
of pain. In order to provide potential cell-based therapies
to increasing patient numbers, it will be necessary to op-
timise the cell choice for isolation, proliferation and sta-
bility to assure the highest patient security. In addition, all
of these new innovative therapies will evolve in relation
to regulatory requirements and more importantly adapted
technical specifications (fig. 4). Biologists and technicians,
in their roles as “laboratory surgeons”, will need to work
even more closely with clinicians to adapt innovative cell
therapeutics to the patient.
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Figures (large format)
Figure 1
Tendon structure, histology and cell culture.
Ultrastructure of tendon showing longitudinal fibres and histological sections stained with haematoxylin and eosin depicting extracellular matrix
colored in pink (~80% composition) and cellular components mainly with tenocytes stained in blue (~20% composition)(horse tendon for
illustration). Primary cultures from tissue can be developed by culturing cells in minimal medium (DMEM + 10% FBS + 1% glutamine) for
approximately 1 week in a monolayer culture to provide “fibroblast-like” pure tenocyte populations (human progenitor tenocytes).
Figure 2
Tendon pathologies and therapeutic strategy.
Tendon pathologies can be either acute or degenerative. Degenerative therapies could be treated with biological cellular therapies with
injectable forms to delay degenerative responses and more invasive surgery. Acute injuries, depending on their severity, could be treated with
either non-invasive to invasive technique with cells in viscous biogels to complex neo-tissue constructs.
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Figure 3
Progenitor human tenocyte cell bank production, capacity and usage for off-the-shelf therapeutic options for tendinopathies.
From one single tendon tissue (2 mm3, organ donation of foetal Achilles tendon tissue at 14 weeks gestation), clinical cell banks can be
produced including parental primary cultures, Master and Working Cell Banks that contain 200 vials each of progenitor tenocytes at low
passages (P. 3–6). Expansion of cells produces high quantities of cells that can be stocked in vapor phase of liquid nitrogen (–165 °C) providing
cell stocks for hundreds of thousands of patients. Cells can be administered in hydrogels or on other delivery systems for testing in animal
models and pre-clinical patient treatments in the process for therapeutic agent development.
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Figure 4
Good Clinical Practice and Good Manufacturing Practice associated with cellular therapeutics.
Current Good Clinical Practices (cGCP) are necessary to begin the process of cellular therapies and tissue engineering with detailed protocols
for organ donation and biopsy processing. Tissue and cellular handling then needs to abide by Current Good Manufacturing Processes (cGMP)
which include specific protocols for infrastructure, equipment and personnel. cGCP is then needed for appropriate administration of cellular
therapies. Thus, the entire process requires high collaboration between biologists, technicians, nurses and surgeons.
Review article: Medical intelligence Swiss Med Wkly. 2014;144:w13989
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 11
Figure 5
Regulatory requirements for cellular therapy products.
Regulatory requirements have become more extensive for cellular therapies and tend towards conservative drug development in their
production, pre-clinical testing and clinical trials. Blood products also have to be produced under cGMP and only in institutions with a license for
manipulation. Organs, cells and tissues (PRP, adipose, bone marrow, skin, cartilage, tendon etc.) need to be processed with environmental
monitoring and full quality assurance with cGMP processing through to the final formulation and delivery to the patient.
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